Focused Issue on Lipid-Modifying Therapies Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Posted On 2019-10-24 02:30:29



This Focused Issue on “Lipid-Modifying Therapies Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)” is edited by Dr. Constantine E. Kosmas, Director of Nuclear Cardiology and Lipid Clinic, Cardiology Unlimited, P.C., New York, NY, USA.

Constantine E. Kosmas, M.D., Ph.D., FACC, FACP is a Clinical/Academic/Non-Invasive cardiologist and Clinical Lipidologist, currently serving as the Director of Nuclear Cardiology and Lipid Clinic at a large private practice in New York (Cardiology Unlimited, P.C.). Dr. Kosmas holds Board Certifications in Cardiovascular Disease, Nuclear Cardiology and Clinical Lipidology in the United States. He has been extensively involved in teaching of mid-level providers, students, medical residents and cardiology fellows at several academic institutions in New York and Pennsylvania. He has also been extensively involved in cardiovascular clinical research with several publications in the medical literature and numerous lectures in academic institutions and national conferences, especially on lipid-related subjects. In addition, he is a member of the Editorial Board, as well as Reviewer for several prestigious peer-reviewed medical journals.

Focused issue outline:

  1. PCSK9: structure, function and genetics
  2. LDL lowering with PCSK9 inhibitors
  3. Non-LDL lipid effects of PCSK9 inhibitors
  4. Impact of PCSK9 inhibitor therapy on cardiovascular outcomes
  5. Safety and tolerability of PCSK9 inhibitors
  6. Non-PCSK9 inhibitor therapies targeting PCSK9